Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SHE:301617)
China
· Delayed Price · Currency is CNY 47.82
+0.48 (1.01%)
At close: May 12, 2025, 2:57 PM CST
SHE:301617 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 1,328 | 1,021 | 796.66 | 523.69 | 378.93 | Upgrade
|
| Other Revenue | - | 3.68 | 1.82 | 0.68 | 0.52 | Upgrade
|
| Revenue | 1,328 | 1,025 | 798.47 | 524.37 | 379.44 | Upgrade
|
| Revenue Growth (YoY) | 29.53% | 28.39% | 52.27% | 38.20% | 12.16% | Upgrade
|
| Cost of Revenue | 998.8 | 739.4 | 520.8 | 347.04 | 265.33 | Upgrade
|
| Gross Profit | 329.08 | 285.75 | 277.67 | 177.33 | 114.12 | Upgrade
|
| Selling, General & Admin | 43.13 | 37.47 | 36.85 | 29.92 | 23.14 | Upgrade
|
| Research & Development | 41.34 | 35.67 | 30.48 | 21.42 | 14.55 | Upgrade
|
| Other Operating Expenses | -3.06 | -0.78 | 3.23 | 1.21 | -0.43 | Upgrade
|
| Operating Expenses | 81.41 | 76.12 | 70.34 | 52.44 | 38.76 | Upgrade
|
| Operating Income | 247.66 | 209.64 | 207.33 | 124.89 | 75.36 | Upgrade
|
| Interest Expense | - | -0 | -0.46 | -1.97 | -3.05 | Upgrade
|
| Interest & Investment Income | - | 1.14 | 0.51 | 0.13 | 6.42 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.11 | 0.35 | -0.02 | -0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.83 | -0.15 | -0.52 | -0.18 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | 249.49 | 210.74 | 207.21 | 122.85 | 78.17 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.58 | -2.31 | -1.85 | -1.4 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | - | 0.34 | - | -0.03 | Upgrade
|
| Asset Writedown | -0.24 | -0.55 | -4.39 | -3.77 | -6.17 | Upgrade
|
| Pretax Income | 244.64 | 207.88 | 201.31 | 117.69 | 71.97 | Upgrade
|
| Income Tax Expense | 31.52 | 25.78 | 24.99 | 14.4 | 7.93 | Upgrade
|
| Net Income | 213.13 | 182.1 | 176.32 | 103.29 | 64.04 | Upgrade
|
| Net Income to Common | 213.13 | 182.1 | 176.32 | 103.29 | 64.04 | Upgrade
|
| Net Income Growth | 17.04% | 3.28% | 70.70% | 61.30% | 269.30% | Upgrade
|
| Shares Outstanding (Basic) | 77 | 77 | 77 | 74 | 73 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 77 | 77 | 74 | 73 | Upgrade
|
| Shares Change (YoY) | 0.15% | - | 4.17% | 0.84% | - | Upgrade
|
| EPS (Basic) | 2.76 | 2.36 | 2.29 | 1.40 | 0.87 | Upgrade
|
| EPS (Diluted) | 2.76 | 2.36 | 2.29 | 1.40 | 0.87 | Upgrade
|
| EPS Growth | 16.95% | 3.19% | 63.88% | 60.41% | - | Upgrade
|
| Free Cash Flow | 105.61 | 79.26 | 53.9 | 11.58 | 11.08 | Upgrade
|
| Free Cash Flow Per Share | 1.37 | 1.03 | 0.70 | 0.16 | 0.15 | Upgrade
|
| Gross Margin | 24.78% | 27.87% | 34.78% | 33.82% | 30.08% | Upgrade
|
| Operating Margin | 18.65% | 20.45% | 25.97% | 23.82% | 19.86% | Upgrade
|
| Profit Margin | 16.05% | 17.76% | 22.08% | 19.70% | 16.88% | Upgrade
|
| Free Cash Flow Margin | 7.95% | 7.73% | 6.75% | 2.21% | 2.92% | Upgrade
|
| EBITDA | 275.94 | 232.51 | 228.5 | 144.2 | 91.33 | Upgrade
|
| EBITDA Margin | 20.78% | 22.68% | 28.62% | 27.50% | 24.07% | Upgrade
|
| D&A For EBITDA | 28.27 | 22.87 | 21.17 | 19.31 | 15.97 | Upgrade
|
| EBIT | 247.66 | 209.64 | 207.33 | 124.89 | 75.36 | Upgrade
|
| EBIT Margin | 18.65% | 20.45% | 25.97% | 23.82% | 19.86% | Upgrade
|
| Effective Tax Rate | 12.88% | 12.40% | 12.41% | 12.23% | 11.02% | Upgrade
|
| Advertising Expenses | - | 1 | 0.46 | 0.21 | 0.09 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.